Zhitong Finance App News, Kangwei Century (688426.SH) issued an announcement. Recently, the company's wholly-owned subsidiary Jiangsu Jianwei Diagnostic Technology Co., Ltd. (“Jianwei Diagnosis”) independently developed a C. difficile TPI and toxin A and toxin B genetic test kit (fluorescence PCR method) obtained a Class III “Medical Device Registration Certificate (in vitro diagnostic reagent)” issued by the China Drug Administration.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.